Tag: Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. BMS is a differentiated company, led by BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. Company’smedicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through its R&D organization, BMS have built a sustainable pipeline of potential therapies and partner with external innovation to broaden and accelerate its work.

Bristol-Myers Squibb entered into a clinical trial collaboration with Compugen

Bristol-Myers Squibb Company and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701.

Bristol-Myers Squibb and Tsinghua University evolve their collaboration

Bristol-Myers Squibb
Bristol-Myers Squibb Company and Tsinghua University (China), have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.

Nativa won a patent dispute with Bristol-Myers Squibb with regard to dasatinib

The Arbitration Court of the Moscow region decided to fully reject the claims filed by Bristol-Myers Squibb Holdings Ireland against Nativa LLC under the case No. A41-87845/2017.

Bristol-Myers Squibb opened its new biologics discovery center

Bristol-Myers Squibb, a global biopharmaceutical company, officially opened the newest building to its Redwood City (California, USA) research and development campus in Woodside Technology Park.

BMS will collaborate with Janssen on a novel cardiovascular therapy

Bristol-Myers Squibb announced a worldwide collaboration with Janssen Pharmaceuticals on a Factor XIa inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’s Factor XIa inhibitor.

Bristol-Myers Squibb started a new collaboration with Nektar Therapautics

Bristol-Myers Squibb Company and Nektar Therapeutics announced a new clinical collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) with Nektar’s investigational medicine, NKTR-214

Sirenas started a research collaboration with Bristol-Myers Squibb

Sirenas, a biotechnology company harnessing computational approaches to discover therapeutics derived from the global microbiome, entered into a multi-target research collaboration agreement with Bristol-Myers Squibb Company

Bristol-Myers Squibb joined ORIEN Avatar Research Program

M2Gen announced that Bristol-Myers Squibb Company has joined the Oncology Research Information Exchange Network® Avatar Research Program

BMS and Halozyme will develop new drug-delivery technology

Bristol-Myers Squibb and Halozyme Therapeutics today announced a global collaboration and license agreement

Bristol-Myers Squibb acquires IFM Therapeutics biotech company

Bristol-Myers Squibb Company and IFM Therapeutics signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics

Seattle Genetics aquired manufacturing facility from Bristol-Myers Squibb

seattle genetics
Seattle Genetics, Inc., a biotechnology company signed definitive agreements to purchase Bristol-Myers Squibb’s pharmaceutical manufacturing facility in Bothell, Washington, USA

Bristol-Myers Squibb sold its manufacturing facility to SK Biotek

Bristol-Myers Squibb Company and SK Biotek Co., Ltd. today announced the companies have signed a definitive purchase agreement

BMS entered a clinical research collaboration with Novartis

Bristol-Myers Squibb Company informed it has entered into a clinical research collaboration with Novartis

Bristol-Myers Squibb enters the collaboration with Array BioPharma

Array BioPharma and Bristol-Myers Squibb Company today announced the companies have entered into a clinical research collaboration

CFDA approved HCV treatment by Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that the China Food and Drug Administration (CFDA) has approved a direct-acting antiviral regimen comprised of Daklinza (daclatasvir) and Sunvepra (asunaprevir),...

Bristol-Myers Squibb made agreements with Biogen and Roche

Bristol-Myers Squibb announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy, to Biogen, and BMS-98608...